Biotech Values

[Rocky3]

There's a disconnect between between the tradeoffs of such a pricing system and the current political noisemaking about such drugs as GILD’s Harvoni (which represents excellent value for the US healthcare system).

Couldn't agree more!!!

And GILD earnings will be interesting. US HCV sales should be down 10-20%, but OUS HCV sales could be up significantly. Japan looks like it could be huge this quarter (and next, but then down in 2Q16 when Japanese price controls kick in). ABBV/ENTA sales in Japan for 1Q16 should also be pretty good. I doubt that there will be much in this quarter, but we will know for sure soon. And we will know the BMY sales everywhere even sooner. I'm expecting BMY WW HCV sales to be larger than ABBV, mainly due to Japan, but that is just a quess. Again, we will know soon.